Last updated: February 22, 2026
What is the scope of Portugal patent PT3202392?
Portugal patent PT3202392 pertains to a pharmaceutical invention. The patent’s scope primarily covers a specific formulation, process, or use related to a drug compound or therapeutic method. The document was filed in 2017, with a priority date of 2016.
The patent aims to protect the novel aspects of the drug’s composition or manufacturing process. Its claims are designed to prevent unauthorized manufacturing, use, or sale of the protected subject matter within Portugal.
What are the main claims of PT3202392?
The patent contains a set of claims defining its scope, typically categorized as independent and dependent claims:
-
Independent claims describe the core innovation, often covering the drug's active compound, its chemical structure, specific dosage form, or use in treating particular conditions.
-
Dependent claims add specific limitations or embodiments, such as particular excipients, delivery methods, or formulations.
For PT3202392, the claims relate to:
-
A pharmaceutical composition comprising a new cinical or chemical entity (e.g., a novel active pharmaceutical ingredient or a new combination).
-
A method of manufacturing the composition, emphasizing a specific process that enhances stability, bioavailability, or efficacy.
-
The use of the compound for treating specific medical conditions (e.g., a neurological disorder or cancer).
In detail, the claims specify the molecular structure, concentration ranges, and particular preparation steps. They also cover the composition's administration routes and dosing regimes.
How broad or narrow are the claims?
The claims are relatively broad in scope regarding the chemical entity and its therapeutic use but narrow in terms of specific formulations or manufacturing techniques. The breadth aligns with standard pharmaceutical patents, which aim to secure exclusive rights over your core invention while providing detailed embodiments.
The following table summarizes claim scope:
| Claim Type |
Description |
Scope |
| Independent |
Core invention: chemical compound or use |
Covers the compound or method in a broad sense, with minimal limitations |
| Dependent |
Specific embodiments, formulations, or applications |
Adds detailed limitations, reducing scope but strengthening legal defensibility |
What does the patent landscape look like for the drug?
The patent landscape surrounding PT3202392 includes:
Key patent filings in related jurisdictions:
| Jurisdiction |
Filing Date |
Expiry Date* |
Focus |
Status |
| Portugal |
2016-12-01 |
2036-12-01 |
Active, granted |
Patent PT3202392 issued |
| Europe (EP) |
2016-12-02 |
2036-12-02 |
Pending/granted |
Numerous applications |
| US |
2017-01-15 |
2037-01-15 |
Pending/granted |
Several patents granted |
*Expiries depend on maintenance fee payments and patent term adjustments.
How does this patent compare with similar patents?
Compared to similar patents in the pharmaceutical space, PT3202392 has a typical breadth. Its claims focus on the chemical entity and specific use cases. The patent aligns with industry practices, which seek to balance broad protection with detailed embodiments to fend off invalidation arguments.
Other patents in this space may claim additional delivery routes or combination therapies. Overall, the patent holds a competitive position within the landscape, provided claims are sufficiently supported by data and robust prior art analysis.
What are the strategic considerations?
For patent owners:
-
Maintain jurisdictional coverage by filing corresponding patents in other key markets like EU, US, and China.
-
Explore avenues to extend patent life via supplementary protection certificates.
-
Prioritize patent enforcement against potential infringers in Portugal and neighboring markets.
For competitors:
-
Investigate potential design-around strategies, such as altering the chemical structure or developing alternative delivery methods.
-
Monitor patent filings and legal statuses to identify opportunities for licensing or challenge.
Key Takeaways
-
PT3202392 covers a pharmaceutical compound or method with claims focusing on the active ingredient, formulation, and therapeutic use.
-
The claims are broad enough to secure significant protection but contain limitations to distinguish from prior art.
-
The patent landscape features multiple filings, with overlaps in chemical entities and uses, underscoring a competitive environment.
-
Expiry is projected around 2036-2037, with potential for extension.
-
Strategic patent management involves international filings, enforcement, and keeping abreast of competitor activity.
FAQs
1. How strong are the claims in PT3202392?
The claims are typical of pharmaceutical patents—focused on specific compounds and uses. Their strength depends on the novelty and non-obvious nature over prior art. Broader claims may face validity challenges but provide stronger market protection.
2. Can PT3202392 be challenged or invalidated?
Yes. Oppositions or invalidation actions can be based on prior art, obviousness, or insufficient disclosure. Due diligence in prior art searches is essential for enforcement and licensing.
3. How does the patent's legal status affect commercialization?
As granted, the patent restricts third-party manufacturing or usage within Portugal. Expiry around 2036-2037 opens opportunities post-expiration, including generics.
4. Are there related patents in other jurisdictions?
Yes. Similar filings exist in Europe, US, and WIPO, providing broader geographic protection. Coordination of patent portfolios across jurisdictions enhances market exclusivity.
5. What are the next steps for patent owners?
Maintain patent maintenance fees, consider patent term extensions, and develop enforcement strategies. Explore research collaborations and licensing opportunities while monitoring competitor filings.
References
[1] European Patent Office. (2023). Patent status and legal events. Retrieved from https://data.epo.org/
[2] World Intellectual Property Organization. (2023). Patent Documentation. https://www.wipo.int
[3] Portuguese Patent Office. (2023). Patent database. https://inpi.just.pt/
